Core Insights - Haleon has been recognized in Fast Company's 2025 Brands That Matter list in the Family of Brands category, highlighting its cultural relevance and consumer connection [1][3] - The recognition reflects Haleon's commitment to delivering science-backed products and supporting everyday health through transparent communication and meaningful initiatives [2][4] Company Overview - Haleon is a leading global consumer health company with a mission to deliver better everyday health, operating across six major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, Wellness, and Sexual Wellness [5] - The company's product portfolio includes well-known brands such as Sensodyne, Centrum, Advil, Voltaren, Emergen-C, and Theraflu, which resonate deeply with consumers [3][5] Brand Strategy - Haleon's diverse portfolio is characterized by strong, distinct brand identities that engage consumers and enrich cultural conversations around wellness and informed self-care [3][4] - The company emphasizes insights-driven innovation, consumer education, and cross-brand collaboration to meet consumer needs and enhance trust [4]

Company Overview - Haleon (HLN) is a British company known for owning brands like "Sensodyne" [1] - The company has a solid business foundation but is experiencing only incremental growth [1] Growth Analysis - The growth trajectory of Haleon appears to be modest, indicating potential challenges in scaling operations or expanding market share [1]

Core Insights - Haleon plc (NYSE:HLN) is experiencing mixed performance, with struggles in North America but strong growth in Latin America and India [2] - The company reported a 0.4% growth in US same-store sales, contrasting with the 1.4% decline that analysts had predicted, indicating a tight consumer economy [2] - Haleon's defensive product line, Sensodyne, saw revenue growth, while discretionary brands experienced a drop in sales [2] - Jim Cramer suggested that Haleon could be likened to a "mini Kenvue," highlighting its potential without the controversies associated with Kenvue [3] Company Performance - Haleon plc sells consumer products, including toothpaste and pain relief items, under well-known brands like Sensodyne and Panadol [2] - The third-quarter earnings report showed a 0.4% increase in US same-store sales, which was better than the expected 1.4% decrease [2] - The performance in North America contrasts with the strong growth in other regions, particularly Latin America and India [2] Market Position - The company is positioned in a tight consumer economy, with mixed results across its product lines [2] - Cramer’s commentary suggests that Haleon has potential as an investment, although there are other AI stocks that may offer higher returns [3]

Hey, I'm Kramer. Welcome to Mad Money. Welcome to Cra, my friends.I'm just trying to save a little money. My job is not just to entertain, but to teach, explain days like today. So, call me 1800 743 CNBC or tweet me at Jim Kramer.We've been very dismissive of this government shutdown on Wall Street. You know why. Because we've been through so many of them, they usually mean nothing to the stock market.Well, it turns out this one is different. The government's now been closed for 37 days with no sign whatsoe ...

Financial Data and Key Metrics Changes - The company achieved 3.4% organic revenue growth in Q3, with a balance of 1.8% from price and 1.6% from volume mix [3][6] - Reported revenue grew by 0.7% in Q3, impacted by a 2.3% drag from divestments and a 0.4% impact from foreign exchange [6][7] - The company is on track to deliver its full-year guidance, expecting organic revenue growth of around 3.5% for 2025 [15][16] Business Line Data and Key Metrics Changes - Oral health grew by 6.9% in Q3, driven by innovation-led premiumization and geographic expansion [7][8] - The business line for pain relief grew by 3.7%, with Panadol showing high single-digit growth [8][9] - Respiratory health declined by 1.8%, while digestive health grew by 2.1% [9][10] Market Data and Key Metrics Changes - North America delivered organic revenue growth of 0.4%, driven by a 0.7% price increase, while volume mix decreased by 0.3% [10][12] - EMEA and LATAM saw organic revenue increase of 5.3%, with price growth at 3.5% and volume mix improvement of 1.8% [12][13] - Asia-Pacific experienced organic revenue growth of 5.1%, with strong performance in India and Southeast Asia [13][14] Company Strategy and Development Direction - The company is focusing on innovation-led premiumization to drive category growth and has made significant progress in its supply chain productivity agenda [5][6] - The company aims to strengthen its innovation pipeline and improve net revenue management through strategic pricing and channel mix [11][12] - The company is closely monitoring the macroeconomic environment in Latin America and expects to adapt its strategies accordingly [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth in North America next year, citing actions taken to improve inventory management and innovation pipeline [21][22] - The company anticipates continued strong growth in Q4, driven by salesforce investment and an improving macro environment [14][15] - Management noted that the consumer health market remains resilient despite macroeconomic pressures, particularly in oral health [58][59] Other Important Information - The company has completed EUR 500 million in share buybacks for 2025 [6] - The company reduced the number of SKUs by 19% since the beginning of 2024, improving gross margin and cash conversion [5][6] Q&A Session Summary Question: North America performance and future expectations - Management noted that the performance in North America was better than expected, driven by oral health and digestive health, with no significant one-offs affecting Q3 results [20][21] Question: Innovation pipeline for 2026 - The company highlighted a strong innovation pipeline across all categories, with no immediate need for RX to OTC switches impacting growth forecasts [28][29] Question: Pricing evolution in EMEA and LATAM - Management acknowledged competitive pressures leading to increased promotional activity, particularly in VMS, while maintaining resilience in oral health [47][72] Question: Category performance and consumer behavior - Management observed a bifurcated consumer environment, with some categories performing well while others struggled, emphasizing the importance of being present across all channels [41][42] Question: Inventory management and channel dynamics - Management confirmed that inventory levels are being adjusted based on consumption trends, with a focus on exiting the year in a clean position [36][66]

Financial Data and Key Metrics Changes - The company achieved 3.4% organic revenue growth in Q3, with a balance of 1.8% from price and 1.6% from volume mix [3][6] - Reported revenue grew 0.7% in Q3, impacted by a 2.3% drag from divestments and 0.4% from foreign exchange [6][7] - The company is on track to deliver its full-year guidance, expecting organic revenue growth of around 3.5% for 2025 [15][16] Business Line Data and Key Metrics Changes - Oral health grew 6.9% in Q3, driven by innovation-led premiumization and geographic expansion [7][8] - The business line for pain relief grew 3.7%, with Panadol showing high single-digit growth [8][9] - Respiratory health declined 1.8%, influenced by the previous year's elevated COVID cases [9][10] - Digestive health grew 2.1%, supported by innovations like TUMS Gummy Bites Plus [9][10] Market Data and Key Metrics Changes - North America delivered organic revenue growth of 0.4%, driven by 0.7% price increase, while volume mix decreased by 0.3% [10][12] - EMEA and LATAM saw organic revenue increase of 5.3%, with price at 3.5% and volume mix at 1.8% [12][13] - Asia-Pacific experienced organic revenue growth of 5.1%, with strong performance in India and Southeast Asia [13][14] Company Strategy and Development Direction - The company focuses on innovation-led premiumization to drive category growth and expand market reach [4][6] - Continued investment in supply chain productivity and cost discipline is emphasized to enhance flexibility and agility in P&L [5][6] - The company aims to strengthen its innovation pipeline and improve net revenue management in North America [11][22] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging consumer backdrop in North America but highlighted outperformance in oral health and digestive health [3][10] - The company expects continued strong growth in Q4, driven by salesforce investment and an improving macro environment [14][15] - Management remains confident in returning to growth in North America next year, with actions in place to address inventory levels [22][66] Other Important Information - The company completed EUR 500 million in share buybacks for 2025 [6] - Significant progress has been made in reducing SKUs by 19%, improving gross margin and working capital [5][80] Q&A Session Summary Question: North America performance and future expectations - Management explained that the sequential improvement in North America was driven by reduced drag from smokers' health and better performance in oral and digestive health [20][21] - Guidance for Q4 suggests around 1% decline, reflecting tough comparatives from the prior year [21][22] Question: Innovation pipeline and cold/flu season outlook - Management confirmed a strong innovation pipeline across categories and noted that the cold and flu season's variability impacts guidance [28][30] Question: Channel dynamics and inventory management - Management discussed the differences in inventory levels across channels, with a focus on ensuring appropriate stock levels for growth next year [35][66] Question: Consumer behavior and market performance - Management highlighted a bifurcated consumer environment, with varying performance across categories and channels [41][42] Question: Oral care business performance - Management acknowledged softer performance in certain oral care brands but remains positive about overall oral health growth [70][72]

Financial Data and Key Metrics Changes - The company achieved 3.4% organic revenue growth in Q3, with a balance of 1.8% from price and 1.6% from volume mix [3][6] - Reported revenue grew by 0.7% in Q3, affected by a 2.3% drag from divestments and a 0.4% impact from foreign exchange [6][7] - The company is on track to deliver its full-year guidance, expecting organic revenue growth of around 3.5% for 2025 [15][16] Business Line Data and Key Metrics Changes - Oral health grew by 6.9% in Q3, driven by innovation and geographic expansion, particularly in markets like the US, India, and China [7][10] - The BMS category grew by 4.9% in Q3, with strong performance from Centrum [8] - Pain relief grew by 3.7%, with Panadol showing high single-digit growth, while respiratory health declined by 1.8% [8][9] - Digestive health grew by 2.1%, supported by innovations in TUMS and Benefiber [9] Market Data and Key Metrics Changes - North America delivered organic revenue growth of 0.4%, driven by oral health and digestive health, despite challenges in the respiratory category [10][11] - EMEA and LATAM saw organic revenue increase of 5.3%, with strong performance in oral health and VMS [11][12] - Asia-Pacific experienced organic revenue growth of 5.1%, with double-digit growth in India and strong performance in Southeast Asia [12][14] Company Strategy and Development Direction - The company is focused on driving category growth through innovation-led premiumization and expanding reach to lower-income consumers [4][5] - Continued investment in supply chain productivity and cost discipline is expected to enhance flexibility and agility in the P&L [5][6] - The company aims to return to growth in North America next year, supported by a strong innovation pipeline and strategic pricing initiatives [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong growth in Q4, driven by salesforce investment and an improving macro environment [14][15] - The company is closely monitoring the macroeconomic environment in Latin America due to consumer pressures [16] - Management highlighted the resilience of the oral health category and the importance of being present across all channels to cater to changing consumer behaviors [41][57] Other Important Information - The company has completed £500 million in share buybacks for 2025 [6] - Significant progress has been made in reducing SKUs by 19%, which is expected to improve gross margin and working capital [5][78] Q&A Session Summary Question: North America performance and future expectations - Management noted that the performance in North America was better than expected, driven by oral health and digestive health, with no one-off benefits impacting Q3 [19][20] - For Q4, a slight decline in organic sales growth is anticipated due to tough comparatives from the prior year [21][22] Question: Innovation pipeline and cold/flu season outlook - The company has a strong innovation pipeline across categories, with no immediate RX to OTC switches expected [27][29] - Guidance for the cold and flu season is based on a normal season assumption, with variability expected [30][31] Question: Consumer behavior and channel dynamics - Management observed a bifurcated consumer environment, with some products performing well while others struggle, and emphasized the importance of being present across all shopping channels [41][42] Question: Pricing evolution in EMEA and LATAM - Management indicated that competitive pressure and promotional activity have increased due to softer consumption, impacting pricing in EMEA and LATAM [46][47] Question: Contribution of innovations and pain franchise performance - Innovations have significantly contributed to growth, with ongoing launches expected to drive future performance [53][54]

Financial Data and Key Metrics Changes - The company revised its sales growth guidance to around 3.5%, while increasing profit guidance to high single digits on an organic basis, driven by a strong productivity program [4][5] - In the U.S., consumption growth was reported at 3.2% at the halfway point of the year, with a slight increase of approximately 0.5% in Q3, contrasting with a market decline of about 0.5% [4][5] Business Line Data and Key Metrics Changes - The company experienced mid-single-digit growth in EMEA, LATAM, and Asia-Pacific regions, with expectations for acceleration in these areas [6] - The oral health segment continued to perform well, with growth in the 3% range, particularly in therapeutic oral health, which is outpacing overall market growth [15][34] Market Data and Key Metrics Changes - The U.S. market is facing muted overall growth and continued inventory pressure, prompting the company to proactively manage inventory with retailers [5][12] - The company noted that the cold and flu season significantly impacted consumption dynamics, with a high season in Q1 followed by a lower allergy season in Q2 [14] Company Strategy and Development Direction - The company is focused on reaching a billion more consumers, particularly in emerging markets, targeting low-income consumers with tailored product launches [10] - There is a strong emphasis on innovation and premiumization in the oral health category, with new product launches and clinical claims expected to drive growth [34][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the revised sales growth target of around 3.5%, despite challenges in the U.S. market [6][62] - The company is optimistic about the potential for growth in the U.S. and emerging markets, with plans to stabilize and improve market share in key categories [25][30] Other Important Information - The company is implementing a productivity program aimed at achieving £800 million in savings by 2030, with expectations of improving gross margins by 50 to 80 basis points annually [50][53] - The recent buyout of the joint venture partner in China is expected to unlock significant operational efficiencies and market potential [43][44] Q&A Session Summary Question: What is the assumption on destocking in the U.S. for the second half? - Management indicated good visibility on inventory levels with top customers and expects continued inventory reduction without significant swings higher [12][13] Question: How is the company executing with growing retailers like Amazon and Walmart? - Management confirmed strong partnerships with major retailers and emphasized the importance of adapting to channel shifts while maintaining consumer access [21][22] Question: What is the outlook for the BMS category in the U.S.? - Management acknowledged challenges in the U.S. BMS market but remains optimistic about new science-backed claims and product innovations driving future growth [28][30] Question: How confident is the company in achieving the 4% to 6% growth target by 2026? - Management expressed confidence in the medium-term guidance, citing a robust strategic planning process and expected improvements in the U.S. market [60][61]

Financial Data and Key Metrics Changes - The company has adjusted its sales growth guidance to around 3.5%, while profit guidance has been raised to high single digits on an organic basis, driven by a strong productivity program [4][5][6] - In the first half of the year, the company achieved a growth rate of 3.2% [4] - Gross margin increased by 160 basis points in the first half of the year [55] Business Line Data and Key Metrics Changes - The U.S. market showed a slight decline, with consumption up by approximately half a point in Q3, while the overall market was down by half a point [4][5] - The company experienced mid-single-digit growth in EMEA, LATAM, and Asia-Pacific regions, with expectations for acceleration in these areas [6] - Oral health performance continued to grow, with a consistent growth rate around 3% [17] Market Data and Key Metrics Changes - The U.S. market faced muted overall growth and continued inventory pressure, leading to a cautious outlook for the remainder of the year [5][6] - The company noted that the cold and flu season significantly impacted consumption dynamics, with a high season in Q1 followed by a lower allergy season in Q2 [15][16] Company Strategy and Development Direction - The company aims to reach a billion more consumers, particularly focusing on low-income consumers in emerging markets [10] - There is a strong emphasis on managing inventory proactively with retailers to avoid out-of-stock situations [5][13] - The company is optimistic about the potential of its brands in emerging markets, particularly in India and China, where it has launched products tailored for low-income consumers [33][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 3.5% growth target, despite challenges in the U.S. market [6][63] - The company is focused on maximizing portfolio performance and improving market share, particularly in oral health and therapeutic categories [26][27] - Management acknowledged the cyclical nature of the market and expressed optimism about returning to growth in the U.S. [63] Other Important Information - The company is implementing a productivity program expected to deliver £800 million in savings by 2030, with a target of 50 to 80 basis points of gross margin improvement annually [52][55] - The company is focused on capital allocation towards automation and building additional plants in strategic locations [60][61] Q&A Session Summary Question: What is the company's outlook on cash flow and working capital? - Management acknowledged the importance of cash flow and indicated that improvements in inventory reduction and working capital could fund capital investments [69][79] Question: How is the company addressing the challenges in the U.S. market? - Management noted that the U.S. market has been challenging but expressed confidence in the potential for recovery and growth [63][80] Question: What is the vision for the new therapeutic skin health category? - Management indicated that the decision to break out therapeutic skin health as a new category was strategic and aimed at capturing growth opportunities [74]

Financial Data and Key Metrics Changes - The company reported a decline in organic sales growth in North America of nearly 2% in Q2, contrasting with growth in EMEA, LatAm, and APAC, which were within the medium-term guidance of 4% to 6% [3][5][14] - Gross margin improved by 160 basis points, contributing to strong cash flow and organic profit growth [5][15] - A&P (Advertising and Promotion) spending increased by 6.8% to 20.8% in the first half of the year, reflecting a focus on growth drivers [16][19] Business Line Data and Key Metrics Changes - In North America, consumption grew slightly ahead of the market, with a 0.5% increase compared to a market decline of 0.5% [9][10] - Oral health and digestive health brands showed strong growth, with market share gains in brands like Tons and Benefiber [9][10] - Centrum experienced mid-single-digit growth outside the US but saw declines in the US, while Emergency brand continued to perform well [11][12] Market Data and Key Metrics Changes - The US market is facing challenges with low consumer confidence and inventory pressures, impacting overall performance [6][8][14] - EMEA and APAC regions showed positive trends, with volume growth accelerating in Q2 [47][51] - Central Europe reported high single-digit growth, while Western Europe experienced mid-single-digit growth, driven by strong performance in oral health [53][54] Company Strategy and Development Direction - The company remains committed to its medium-term guidance of 4% to 6% organic sales growth despite current challenges in the US market [49][56] - Focus on innovation and premiumization, particularly in key markets like India and Brazil, is part of the strategic plan [39][40] - The company aims to close the incidence treatment gap and expand reach to lower-income consumers while maintaining investment in A&P and R&D [16][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging consumer environment in the US, with expectations of continued inventory pressure and no significant improvement anticipated in the near term [14][22] - Confidence in the medium-term outlook remains strong, with expectations for improved performance in 2026 [49][56] - The company is actively managing its portfolio and focusing on driving market growth despite external challenges [36][41] Other Important Information - The nicotine replacement therapy (NRT) business is a significant part of the portfolio, with a complex ownership structure affecting innovation and growth [73][75] - The company expects a high single-digit growth in operating profit, supported by gross margin improvements and effective cost control [77][78] Q&A Session Summary Question: North America's performance and future growth expectations - Management noted that North America faced challenges due to a difficult consumer environment and inventory pressures, with expectations for a gradual return to growth [3][22][25] Question: A&P spending and areas of reinvestment - A&P spending increased significantly, with a focus on driving growth in key markets and improving ROI [16][19] Question: Share performance and competitive pressures - The decline in the percentage of business gaining or maintaining share was attributed to challenges with brands like Advil and Centrum, with plans in place to stabilize performance [28][30] Question: Impact of nicotine replacement therapy on growth - The NRT business had a significant impact on overall growth, with expectations for less decline in the second half of the year [76][80] Question: Channel shifts and inventory management - Management discussed the impact of channel shifts, particularly towards e-commerce, and the need for effective inventory management across channels [86][90]